EUVIMEDDescoperă EUVIMED
CrossrefCard informativ

Optimizing treatment strategies for early‐onset mucinous adenocarcinoma of the colon: A SEER database analysis

Cameron Perrone, Sameh Hany Emile, Christopher Lopez, Spencer Barnes, Anjelli Wignakumar, Matthew Bilotti, Steven D. Wexner

Colorectal Disease · 2026-02 · 28 (2)

DOI: 10.1111/codi.70390 ↗
RezumatDate bibliografice

Rezumat

Abstract Background Colorectal mucinous adenocarcinoma (MAC) is challenging due to its unique pathophysiology and increasing incidence in younger populations. Treatment guidelines for early‐onset MAC remain unclear, with clinical decisions often based on extrapolated data from classical adenocarcinoma. We aimed to assess the association between the extent of surgical resection and systemic therapy in patients with early‐onset colonic MAC and survival. Methods Retrospective cohort analysis of patients aged 20–50 with stage II–III colonic MAC using the SEER database (2000–2020). We evaluated overall survival (OS) and cancer‐specific survival (CSS) based on surgical resection (segmental vs. extended) and systemic therapy, using Kaplan–Meier and Cox regression analyses. Results The cohort included 2553 patients (58.5% male; mean age 42.7 years). Segmental resection was performed in 27.6%. Extended resection was more commonly performed in right‐sided and stage III disease. Systemic therapy was administered to 62.1%, predominantly for stage III disease with unfavourable tumour features. Systemic therapy was associated with improved restricted mean 5‐year CSS (51.7 vs. 47.8 months, p = 0.041) and OS (51.1 vs. 45.9 months, p = 0.008) in stage III, but not stage II, disease. Extended resection was associated with a modest survival benefit for CSS (56.5 vs. 54.3 months, p = 0.027) and OS (56.0 vs. 53.3 months, p = 0.007) in stage II, but not stage III, disease. Conclusion Systemic therapy was associated with a significant survival benefit in patients with stage III early‐onset MAC, supporting its role as a cornerstone of treatment despite the histology's presumed chemoresistance.

Cunoștințe potrivite muncii dumneavoastră.

De la începutul gratuit și cercetarea bibliografică personală până la Research Suite complet.

Vezi tarifele →

Sunt incluse toate textele integrale ale editorilor?

Nu. Referințele bibliografice, rezumatele și textele integrale sunt conținuturi diferite. Disponibilitatea unui text integral depinde de sursă, de Open Access și de licențele pe care le aveți deja. Un abonament EUVIMED nu înlocuiește drepturile suplimentare ale editorilor.

Vezi tarifele →